文献速递银屑病与炎症性皮肤病

司库奇尤单抗省略初始负荷剂量治疗慢性斑块状银屑病的疗效

Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis.
PubMed 文献 · Br J Dermatol · 2019-05-29

该回顾性观察研究纳入156例成人银屑病患者,比较司库奇尤单抗300mg按标签剂量(含初始负荷,n=75)与省略初始负荷剂量(n=81)的疗效。省略负荷剂量组第8、12周PASI 75和PASI 90应答率显著低于标签剂量组,但第16周后两组疗效相似;省略负荷剂量组因无效停药比例更高,尤其体重>80kg者。

要点

  • 省略初始负荷剂量在第8、12周PASI应答显著劣于标签剂量。
  • 第16周至第48周两组PASI 75和PASI 90应答率相似。
  • 省略负荷剂量组因无效停药比例更高,体重>80kg者更明显。

核心结论

  • 司库奇尤单抗省略初始负荷剂量与更高的原发无效比例相关,第8周和第12周疗效劣于标签剂量,但此后疗效相似。

研究设计与样本

  • 回顾性观察性研究,纳入156例接受司库奇尤单抗300mg治疗的成人银屑病患者,按标签剂量(n=75)与省略初始负荷剂量(n=81)分组比较。

临床怎么用

  • 临床中省略司库奇尤单抗初始负荷剂量可能导致短期疗效不足和原发无效,尤其体重>80kg者应谨慎。

局限性

  • 回顾性观察性设计,可能存在选择偏倚和混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secukinumab is administered at the labelled dose of 300 mg at weeks 0, 1, 2, 3, 4 (loading dose) and every 4 weeks thereafter. OBJECTIVES: To investigate the efficacy of secukinumab administered without the initial loading dose in patients with psoriasis. METHODS: This was a retrospective observational study including adult patients with psoriasis (n = 156) treated with secukinumab 300 mg administered either according to the labelled dose (n = 75) or without the initial loading dose (n = 81). Efficacy was evaluated by comparing the Psoriasis Area and Severity Index (PASI) 75 and PASI 90 response rates at week 8, 12, 16, 32 and 48. RESULTS: For patients who received the labelled dose vs. those who did not, PASI 75 response rates were achieved at week 8, 12, 16, 32 and 48 by 60% vs. 40% (P < 0·01), 72% vs. 61% (P < 0·01), 77% vs. 75%, 85% vs. 77% and 79% vs. 78%, respectively. PASI 90 responses were achieved at the same time points by 45% vs. 31% (P < 0·01), 49% vs. 40% (P < 0·01), 54% vs. 47%, 55% vs. 47% and 57% vs. 54% for those who received the labelled dose vs. those who did not, respectively. A greater proportion of patients receiving secukinumab without the loading dose discontinued treatment because of inefficacy (25% vs. 13%, P < 0·05), particularly those with body weight greater than 80 kg. CONCLUSIONS: Secukinumab administered without the loading dose is associated with a higher proportion of primary inefficacy, and achieved inferior results compared with the labelled dose at week 8 and week 12, but showed similar efficacy thereafter. What's already known about this topic? Secukinumab is an interleukin (IL)-17A inhibitor for chronic plaque psoriasis administered by subcutaneous injections at the labelled dose of 300 mg at weeks 0, 1, 2, 3, 4 (loading dose) and every 4 weeks thereafter (maintenance dose). Dose adjustment is common in clinical practice, and can consist of dose reduction when a prolonged remission is obtained or a dose increase in order to improve efficacy. What does this study add? The efficacy of secukinumab administered without the initial weekly loading dose was significantly inferior compared with the labelled dose in the short term, but was similar after week 16 and up to week 48. A greater proportion of patients receiving secukinumab without the loading dose showed primary inefficacy, particularly those with body weight greater than 80 kg.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Gisondi P, Rovaris M, Piaserico S, et al. Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis. Br J Dermatol. 2019. PMID: 31004509. doi:10.1111/bjd.18015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。